Answers are grounded in this paper and cite their sources.
This review outlines the design features and anatomical considerations of emerging percutaneous left atrial appendage ligation and exclusion technologies for stroke prevention in non-valvular atrial fibrillation.
Stroke is the most feared complication of atrial fibrillation (AF). Targeting the left atrial appendage (LAA) mechanically is attractive as a means to simultaneously reduce stroke risk, the need for anticoagulation, and hemorrhagic complications in patients with non-valvular AF. The results of the PROTECT-AF and PREVAIL randomized clinical trials support this approach as a viable therapeutic alternative to warfarin in selected patients and add to accumulating evidence regarding the importance of the LAA in thromboembolism in AF. A number of devices for percutaneous LAA closure are under investigation or development. In this article, key design features of these ligation and exclusion technologies will be discussed, with a focus on aspects of LAA morphology, relational anatomy, thrombosis, and thromboembolism relevant for successful device development and deployment.
No takes yet. Share an insight, caveat, or question.
Syed et al. (2015) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: